Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Bladder Cancer

  Free Subscription

Articles published in Br J Cancer

Retrieve available abstracts of 20 articles:
HTML format

Single Articles

    April 2022
  1. ZHOU Z, Zhang Z, Chen H, Bao W, et al
    SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling.
    Br J Cancer. 2022 Apr 28. pii: 10.1038/s41416-022-01794.
    PubMed     Abstract available

  2. DE JONG JJ, Valderrama BP, Perera J, Juanpere N, et al
    Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis.
    Br J Cancer. 2022 Apr 21. pii: 10.1038/s41416-022-01799.
    PubMed     Abstract available

    March 2022
  3. LETT L, George M, Slater R, De Lacy Costello B, et al
    Investigation of urinary volatile organic compounds as novel diagnostic and surveillance biomarkers of bladder cancer.
    Br J Cancer. 2022 Mar 29. pii: 10.1038/s41416-022-01785.
    PubMed     Abstract available

  4. NARII N, Sobue T, Zha L, Kitamura T, et al
    Vegetable and fruit intake and the risk of bladder cancer: Japan Public Health Center-based prospective study.
    Br J Cancer. 2022 Mar 3. pii: 10.1038/s41416-022-01739.
    PubMed     Abstract available

    February 2022
  5. CHEN J, Rodopoulou S, Strak M, de Hoogh K, et al
    Long-term exposure to ambient air pollution and bladder cancer incidence in a pooled European cohort: the ELAPSE project.
    Br J Cancer. 2022 Feb 16. pii: 10.1038/s41416-022-01735.
    PubMed     Abstract available

  6. JIN K, Yu Y, Zeng H, Liu Z, et al
    CD103(+)CD8(+) tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer.
    Br J Cancer. 2022 Feb 14. pii: 10.1038/s41416-022-01725.
    PubMed     Abstract available

  7. SHOHDY KS, Villamar DM, Cao Y, Trieu J, et al
    Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.
    Br J Cancer. 2022;126:430-439.
    PubMed     Abstract available

    January 2022
  8. LIU Z, Zeng H, Jin K, Yu Y, et al
    TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
    Br J Cancer. 2022 Jan 17. pii: 10.1038/s41416-022-01703.
    PubMed     Abstract available

    November 2021
  9. IKARASHI D, Kitano S, Tsuyukubo T, Takenouchi K, et al
    Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting.
    Br J Cancer. 2021 Nov 15. pii: 10.1038/s41416-021-01628.
    PubMed     Abstract available

    October 2021
  10. ROSE TL, Weir WH, Mayhew GM, Shibata Y, et al
    Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.
    Br J Cancer. 2021;125:1251-1260.
    PubMed     Abstract available

    September 2021
  11. SILVERS CR, Messing EM, Miyamoto H, Lee YF, et al
    Tenascin-C expression in the lymph node pre-metastatic niche in muscle-invasive bladder cancer.
    Br J Cancer. 2021 Sep 25. pii: 10.1038/s41416-021-01554.
    PubMed     Abstract available

    April 2021
  12. KHAN MT, Irlam-Jones JJ, Pereira RR, Lane B, et al
    A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer.
    Br J Cancer. 2021 Apr 12. pii: 10.1038/s41416-021-01326.
    PubMed     Abstract available

    March 2021
  13. TEO MY, Al-Ahmadie H, Seier K, Tully C, et al
    Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.
    Br J Cancer. 2021;124:1214-1221.
    PubMed     Abstract available

    February 2021
  14. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available

    September 2020
  15. VOSS MH, Gordon MS, Mita M, Rini B, et al
    Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
    Br J Cancer. 2020 Sep 11. pii: 10.1038/s41416-020-01041.
    PubMed     Abstract available

    August 2020
  16. REZENDE LFM, Lee DH, Keum N, Wu K, et al
    Resistance training and total and site-specific cancer risk: a prospective cohort study of 33,787 US men.
    Br J Cancer. 2020;123:666-672.
    PubMed     Abstract available

    July 2020
  17. PATTARAWAT P, Hong T, Wallace S, Hu Y, et al
    Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma.
    Br J Cancer. 2020;123:226-239.
    PubMed     Abstract available

    December 2019
  18. BENGTSEN MB, Veres K, Norgaard M
    First-time postmenopausal bleeding as a clinical marker of long-term cancer risk: A Danish Nationwide Cohort Study.
    Br J Cancer. 2019 Dec 6. pii: 10.1038/s41416-019-0668.
    PubMed     Abstract available

    November 2019
  19. KITA Y, Hamada A, Saito R, Teramoto Y, et al
    Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies.
    Br J Cancer. 2019 Nov 1. pii: 10.1038/s41416-019-0609.
    PubMed     Abstract available

    March 2019
  20. IHIRA H, Sawada N, Yamaji T, Goto A, et al
    Physical activity and subsequent risk of kidney, bladder and upper urinary tract cancer in the Japanese population: the Japan Public Health Centre-based Prospective Study.
    Br J Cancer. 2019;120:571-574.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.